Afirma XA:

• Informs selection of surgical and therapeutic decisions for Afirma GSC Suspicious, Bethesda V, and Bethesda VI nodules¹
• Is clinically validated¹ and informed by The Cancer Genome Atlas (TCGA),² extensive published literature,
  and Veracyte R&D discovery using nearly 40,000 samples³
• Is the largest thyroid gene and fusion panel available, comprised of 593 genes, 905 variants, and 235 fusion pairs³